KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Effect of Group Logotherapy on Anxiety About Death and Existential Loneliness in Patients With Advanced Cancer: A Randomized Controlled Trial. PMID 35583988 · Cancer Nurs · 2023 Jan This is a randomized, controlled trial in advanced cancer patients assessing a psychotherapy intervention (group logotherapy) for anxiety and loneliness. While it meets criteria for being human, oncology, randomized, and an original primary result, it is ineligible because: 1) The intervention is not a drug-containing therapy. 2) The primary endpoints are anxiety about death and existential loneliness, which are not time-to-event efficacy endpoints (e.g., OS, PFS, DFS, HR). 3) The study phase is not specified as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Time trends in health-related quality of life assessment and reporting within publications of oncology randomised phase III trials: a meta-research study. PMID 39886519 · BMJ Oncol · 2023 The record describes a meta-research study on reporting trends for quality of life endpoints across multiple oncology trials, not an original result report from a single randomized Phase III trial with a drug intervention and a time-to-event efficacy endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A clustered randomized controlled trial of symptom screening and automatic referral for supportive care for patients with GI cancer care needs. PMID 38919584 · Can Oncol Nurs J · 2023 The record does not meet key eligibility criteria: it is not a definitive Phase III/IIIb or Phase II/III trial, lacks a drug intervention, and does not have a time-to-event primary/key secondary efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Real-world data in patients with BRCA mutated breast cancer treated with poly (ADP-ribose) polymerase inhibitors. PMID 38414963 · Ecancermedicalscience · 2023 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial. PMID 38406172 · Front Oncol · 2023 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A triple-masked, two-center, randomized parallel clinical trial to assess the superiority of eight weeks of grape seed flour supplementation against placebo for weight loss attenuation during perioperative period in patients with cachexia associated with colorectal cancer: a study protocol. PMID 38313843 · Front Endocrinol (Lausanne) · 2023 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study). PMID 38288117 · Front Immunol · 2023 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Could setmelanotide be the game-changer for acquired hypothalamic obesity? PMID 38239988 · Front Endocrinol (Lausanne) · 2023 The record describes a commentary on a planned/randomized trial (setmelanotide for acquired hypothalamic obesity) that is currently recruiting. It is not an original formal result report of a completed randomized trial. The publication type is 'Randomized Controlled Trial' but the content is a commentary/discussion, not primary results. No time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR) is reported or implied. The study is in an oncology context (craniopharyngioma, hypothalamic obesity post-treatment) but lacks the required result-report characteristics.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Dietary intervention for tertiary prevention in head and neck squamous cell carcinoma survivors: clinical and translational results of a randomized phase II trial. PMID 38239654 · Front Oncol · 2023 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Neurological mechanism and efficacy of acupuncture for breast cancer-related insomnia: a study protocol for randomized clinical trial. PMID 38187141 · Front Neurol · 2023 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
The influence of herbal medicine on serum motilin and its effect on human and animal model: a systematic review. PMID 38161695 · Front Pharmacol · 2023 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The dose-response effect of aerobic exercise on inflammation in colon cancer survivors. PMID 38148846 · Front Oncol · 2023 The study is a randomized dose-response trial in colon cancer survivors, but it is not a Phase III/IIIb or Phase II/III drug trial. The primary endpoint is inflammation biomarkers (hs-CRP, IL6, sTNFαR2), not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). Therefore, it does not meet the eligibility criteria for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of anti-CD38 monoclonal antibodies in patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials. PMID 38144527 · Front Oncol · 2023 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The Effects of Laughter Yoga on Perceived Stress, Positive Psychological Capital, and Exercise Capacity in Lung Cancer Chemotherapy Patients: A Pilot Randomized Trial. PMID 38102816 · Integr Cancer Ther · 2023 The study is a pilot randomized trial assessing non-oncologic endpoints (perceived stress, psychological capital, exercise capacity). It lacks Phase III/definitive trial designation and a primary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR, Kaplan-Meier).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Clinical effect of high-flow nasal cannula oxygen therapy combined with naloxone on severe respiratory failure in older adult patients: a randomized controlled trial. PMID 38074811 · Am J Transl Res · 2023 Study is not in the domain of oncology; it evaluates respiratory failure treatments, not cancer therapies.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
An update on combination therapies for multiple sclerosis: where are we now? PMID 38058171 · Expert Rev Neurother · 2023 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Lung-heart toxicity in a randomized clinical trial of hypofractionated image guided radiation therapy for breast cancer. PMID 38053657 · Front Oncol · 2023 The study is a randomized trial with a time-to-event endpoint in human oncology, but it does not meet all eligibility criteria. The intervention is hypofractionated image-guided radiation therapy, not a drug-containing intervention, which is a required criterion. Phase evidence is unclear from the metadata. Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prevention of new-onset atrial fibrillation in elderly patients undergoing anatomic pulmonary resection by infusion of magnesium sulfate: protocol for a randomized controlled trial. PMID 38045914 · Front Cardiovasc Med · 2023 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Eflornithine for chemoprevention in the high-risk population of colorectal cancer: a systematic review and meta-analysis with trial sequential analysis. PMID 38033490 · Front Oncol · 2023 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
A randomized controlled trial to explore the safety and efficacy of irradiated buffy-coat granulocytes in pediatric patients with febrile neutropenia. PMID 38023414 · Am J Blood Res · 2023 The record describes a randomized trial in pediatric oncology patients with febrile neutropenia, but the intervention is a granulocyte transfusion (a biological product), not a drug. The trial phase is not specified in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparison of the survival outcomes of laparoscopic, abdominal and gasless laparoscopic radical hysterectomy for early-stage cervical cancer: trial protocol of a multicenter randomized controlled trial (LAGCC trial). PMID 38023150 · Front Oncol · 2023 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Autologous CIK cells combined with chemotherapy as the first-line treatment for locally advanced or metastatic gastric cancer is safe and feasible. PMID 38022664 · Front Immunol · 2023 The record describes a randomized, controlled oncology trial with drug intervention and primary time-to-event endpoints (PFS, OS) reported. However, the trial phase is not explicitly established as Phase III/IIIb or Phase II/III. The abstract describes it as an 'exploratory trial,' and the metadata indicates unclear phase evidence. Without explicit confirmation of a Phase III/IIIb or Phase II/III design, the primary eligibility criterion is not met.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of XELOX combined with anlotinib and penpulimab vs XELOX as an adjuvant therapy for ctDNA-positive gastric and gastroesophageal junction adenocarcinoma: a protocol for a randomized, controlled, multicenter phase II clinical trial (EXPLORING study). PMID 38022553 · Front Immunol · 2023 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Colorectal cancer screening-what does the recent NordICC trial mean for the U.S. population? PMID 38021363 · Transl Gastroenterol Hepatol · 2023 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Establishment and Validation of a Postoperative VTE Prediction Model in Patients with Colorectal Cancer Undergoing Radical Resection: CRSPOT Nomogram. PMID 37997283 · Clin Appl Thromb Hemost · 2023 The study is an oncology, human, randomized retrospective analysis for building a predictive model, but it is not a Phase III/definitive trial, does not test a drug intervention, and does not report a primary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I/IIa MULTIVIR-01 study. PMID 37965339 · Front Immunol · 2023 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Tailored Prevention of Functional Decline through a Multicomponent Exercise Program in Hospitalized Oncogeriatric Patients: Study Protocol for a Randomized Clinical Trial. PMID 37960915 · J Nutr Health Aging · 2023 This is a protocol for a randomized trial of a non-drug exercise intervention in oncogeriatric patients. It does not meet key inclusion criteria: it is not a Phase III trial, lacks a drug intervention, and does not have a primary time-to-event efficacy endpoint (the primary endpoint is change in functional capacity via SPPB).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance. PMID 37942277 · Ther Adv Musculoskelet Dis · 2023 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Hula as a physical activity and social support intervention for sustained activity in female breast and gynecologic cancer survivors. PMID 37941759 · Front Psychol · 2023 The record describes a randomized controlled trial of a non-drug (hula/physical activity) intervention in cancer survivors. While it is oncology, human, and randomized, it lacks a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Community-Based Recruitment Strategies for Young Adult Pacific Islanders into a Randomized Community Smoking Cessation Trial. PMID 37934445 · Prog Community Health Partnersh · 2023 The record describes a randomized, human, oncology-related (smoking cessation for lung cancer prevention) study, but it is not a Phase III/IIIb or Phase II/III trial of a drug intervention with a time-to-event efficacy endpoint. It is a non-drug cessation program study focusing on recruitment methods.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Multivariate Prognostic Models for Patients with Stages I and Ii Colon Carcinoma: a Strobe-Compliant Retrospective Cohort Study. PMID 37918013 · Rev Invest Clin · 2023 The record describes a retrospective cohort study developing prognostic models, not a randomized controlled trial of a drug intervention. It lacks a therapeutic intervention, a trial phase, and randomization to treatment arms.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma-a phase II trial of the AIO study group (AIO STO 0321). PMID 37909020 · Front Oncol · 2023 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A randomized controlled trial of teprenone in terms of preventing worsening of COVID-19 infection. PMID 37883347 · PLoS One · 2023 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Regorafenib alone or in combination with high/low-dose radiotherapy plus toripalimab as third-line treatment in patients with metastatic colorectal cancer: protocol for a prospective, randomized, controlled phase II clinical trial (SLOT). PMID 37869085 · Front Oncol · 2023 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Comparative efficacy and safety of novel immuno-chemotherapy for extensive-stage small-cell lung cancer: a network meta-analysis of randomized controlled trial. PMID 37846397 · Ther Adv Med Oncol · 2023 This is a network meta-analysis (a type of systematic review and meta-analysis) synthesizing results from multiple existing RCTs, not an original formal-result report of a single Phase III or II/III randomized trial. While the underlying included trials are randomized, oncology, and involve drug interventions, the publication itself is a secondary analysis and thus ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effects of imipramine on cancer patients over-expressing Fascin1; description of the HITCLIF clinical trial. PMID 37841433 · Front Oncol · 2023 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Influence of Humoral Response Against GnRH, Generated by Immunization with a Therapeutic Vaccine Candidate on the Evolution of Patients with Castration-Sensitive Prostate Adenocarcinoma. PMID 37828833 · Technol Cancer Res Treat · 2023 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The Auxiliary Effects of Low-Molecular-Weight Fucoidan in Locally Advanced Rectal Cancer Patients Receiving Neoadjuvant Concurrent Chemoradiotherapy Before Surgery: A Double-Blind, Randomized, Placebo-Controlled Study. PMID 37822243 · Integr Cancer Ther · 2023 The study is a randomized, placebo-controlled oncology trial, but it does not explicitly report Phase III/IIIb or Phase II/III status, and its primary endpoints are quality-of-life and safety outcomes, not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.). The intervention is a dietary supplement (fucoidan), not a standard drug therapy for efficacy evaluation.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Response assessment of post-treatment head and neck cancers to determine further management using NI-RADS (Neck Imaging Reporting and Data System): a subgroup analysis of a randomized controlled trial. PMID 37810970 · Front Oncol · 2023 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Risk factors and predictive model for recurrence in papillary thyroid carcinoma: a single-center retrospective cohort study based on 955 cases. PMID 37810888 · Front Endocrinol (Lausanne) · 2023 Eligibility criteria not met: the study is not a Phase III/IIIb or Phase II/III randomized drug trial, does not involve a drug intervention, and lacks a primary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effects of nebulized hypertonic saline on inflammatory mediators in patients with severe COVID-19 pneumonia: A double-blinded randomized controlled trial. PMID 37787398 · Sci Prog · 2023 Study is a randomized controlled trial in humans with a drug-containing intervention (nebulized hypertonic saline) and reports original results. However, it is not an oncology/malignant neoplasm study (focus is COVID-19 pneumonia), and it does not report a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.). Outcomes are inflammatory biomarkers and clinical metrics (mortality rate, intubation rate, length of stay), but not time-to-event with Kaplan-Meier or hazard ratios.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparative study of concurrent conventional chemoradiotherapy versus hypofractionated chemoradiotherapy in newly diagnosed glioblastoma multiforme postoperative patients. PMID 37787273 · J Cancer Res Ther · 2023 The study meets most criteria but lacks explicit confirmation of being a Phase III/IIIb or Phase II/III randomized trial. The record does not provide enough evidence to establish the trial phase, which is required for eligibility.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Combined early palliative care for non-small-cell lung cancer patients: a randomized controlled trial in Chongqing, China. PMID 37781179 · Front Oncol · 2023 The study is a randomized controlled trial in oncology with a primary time-to-event endpoint (OS), but the intervention is non-drug-only (early palliative care), which is an exclusion criterion. The trial phase is not specified as Phase III/IIIb or Phase II/III in the metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of Super-Bioavailable Itraconazole and Conventional Itraconazole at Different Dosing Regimens in Glabrous Tinea Infection - A Randomized Clinical Trial. PMID 37766823 · Drug Des Devel Ther · 2023 The study is a randomized clinical trial evaluating the efficacy of itraconazole formulations for a fungal infection (tinea), not for a human malignant neoplasm. It lacks a Phase III classification and does not include a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, Kaplan-Meier, HR). Therefore, it is excluded from the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint inhibitors in combination with radiotherapy. PMID 37744345 · Front Immunol · 2023 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A Nomogram to Predict the Overall Survival of Patients With Resected T1-2N0-1M0 Non-Small Cell Lung Cancer and to Identify the Optimal Candidates for Adjuvant Chemotherapy in Stage IB or IIA Non-Small Cell Lung Cancer Patients. PMID 37703536 · Cancer Control · 2023 The study is a retrospective prognostic model development using a database, not a randomized trial of a drug intervention. It randomly divided patients for model building but did not randomize them to chemotherapy vs. no chemotherapy as a trial intervention. The publication type 'Randomized Controlled Trial' in metadata is incorrect for the actual study design.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced/Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-Based External Control Arm. PMID 37701519 · J Health Econ Outcomes Res · 2023 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Clinical protocol: Feasibility of evaluating abemaciclib neuropharmacokinetics of diffuse midline glioma using intratumoral microdialysis. PMID 37682953 · PLoS One · 2023 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. PMID 37664025 · Front Oncol · 2023 The record describes a subgroup analysis of the CLEAR Phase III trial, not the original formal result report. The abstract explicitly states it 'explores outcomes in patients with or without specific prognostic features' and the conclusion notes these findings 'corroborate those of the primary CLEAR study analysis.' This is a secondary, post-hoc subgroup analysis, which is excluded by the adjudication rules.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prognostic Factors and a Predictive Nomogram of Cancer-Specific Survival of Epithelial Ovarian Cancer Patients with Pelvic Exenteration Treatment. PMID 37637510 · Int J Clin Pract · 2023 The study is excluded because it is not a randomized trial of a drug-containing intervention. It is a retrospective prognostic nomogram study using registry data, which does not meet the requirement for a drug-containing intervention in a randomized controlled trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -